Two active federal MDLs now define the current landscape
The April 1, 2026 JPML report shows two GLP-1 product-liability MDLs that matter right now. MDL 3094 covers the larger GI-injury track, while MDL 3163 is the separate NAION vision-loss track.
That split matters for content and for screening. GI and sudden-vision-loss claims should not be blended into one generic page or one generic intake bucket because the medical facts, records, experts, and litigation theories are different.
What changed in 2026
The most important 2026 regulatory shift so far is FDA's January 13, 2026 request to remove suicidal-behavior and ideation language from obesity GLP-1 labels after the agency found no increased risk. That makes the mental-health topic much weaker than it looked in older screenshots or older label versions.
The current February 2026 Wegovy label also matters because it still gives the clearest public framework for severe GI reactions, pregnancy timing, diabetic retinopathy monitoring, and the thyroid boxed warning. It is the label version the site should be anchored to, not older 2024 or 2025 PDFs.
What currently makes a stronger screened inquiry
A useful public example is Levin Papantonio's GLP-1 intake criteria sheet. That public document screens heavily for brand-name drug use, a qualifying diagnosis, timing close to drug use, ER or hospital treatment, and whether the person already has a lawyer.
That does not mean every firm uses the same checklist. It does show the general shape of a stronger inquiry: brand-name product, objective diagnosis, clear timing, significant treatment, and records that tie the event together.
Which research and trials are worth watching now
The research topics that matter most right now are severe GI injury, gastric retention, and NAION. That is why current semaglutide site content should track FDA and JPML materials together with ophthalmology research and the newer gastric-retention studies.
ClinicalTrials.gov listings on gastric contents, semaglutide-induced gastric retention, and reproductive or IVF questions are also worth watching because even when they are not lawsuit studies, they can shift the public evidence base and the search behavior around the drug class.